Alessandro Riva

Alessandro Riva is currently the Chief Executive Officer at Intima Bioscience. Previously, Alessandro was the Chief Executive Officer and a Board Member at Ichnos Sciences, a biotechnology company advancing bi/trispecific antibody cancer therapeutics and biologics targeting autoimmune diseases. Prior to joining Ichnos, Alessandro was the Executive Vice President and Global Head of Oncology Therapeutics and Cell Therapy at Gilead Sciences, where he led the company’s acquisition of Kite Pharma. Alessandro also served as the Executive Vice President Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals and was President ad interim of Novartis Oncology during the acquisition of GSK Oncology. He previously held roles at Farmitalia Carlo Erba, Rhône-Poulenc Rorer and Aventis and co-founded the Breast Cancer International Research Group (BCIRG) and the Cancer International Research Group (CIRG). Alessandro received his BMBS and MD in Oncology/Hematology from the University of Milan.